What Can Peptides Really Do? (0018)

Peptides are being sold as the future of weight loss, injury recovery, muscle growth and longer life. But the word covers everything from insulin and established prescription medicines to experimental compounds with very little human evidence. Ruth and Luke explore how peptides communicate with the body, why different patients respond differently, and which benefits are supported by science. They examine GLP-1 medicines, growth-hormone pathways, tissue-repair claims, mitochondrial treatments, collagen and more. Then they follow the money. From Novo Nordisk and Eli Lilly to emerging developers and specialist manufacturers, who could benefit if peptide medicines keep expanding? What happens to healthcare costs, insurance, food businesses and access to treatment? A deep dive into the biology, the promises and the commercial incentives behind the peptide boom.